MECS Medical and Clinical Studies Cottbus GmbH

Cottbus 14 trials 2 recruiting

14 Registered trials

2 Currently recruiting

Organisation

MECS Medical and Clinical Studies Cottbus GmbH

Location

Cottbus, Germany

Identifier

ORG-100041210

Address

Thiemstrasse 124, Spremberger Vorstadt, 03050, Germany

Departments

-
4509: Pulmonology
MECS Cottbus GmbH
MECS Cottbus GmbH (#1)
N/A
NA
Pneumologie
Pulmonology

Clinical trials at this site (14)

Search interface

An Open-Label Extension to Study the Long-Term Effect of Dexpramipexole in Participants with Severe Eosinophilic Asthma (EXHALE-5) Under evaluation

2024-510810-33-00 Severe eosinophilic asthma 5 2024-10-14
BETRI-Prospective: Asthma control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 µg]) vs Single Inhaler ICS/LABA (200/… Pending

2025-524289-56-00 Asthma 6
Therapeutic equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in subjects with mild to moderate asthma (TRECONY) Recruiting

2025-521456-35-00 Mild to moderate asthma 4 2026-04-13
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in C… Recruiting

2023-507407-59-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2024-07-04
Study to assess whether Verekitug can improve the control of Chronic Obstructive Pulmonary Disease (COPD) Ended

2025-520488-42-00 Moderate-to-Severe Chronic Obstructive Pulmonary Diseas 4 2025-09-17
A trial to learn how well benralizumab works and how safe it is when given in addition to standard asthma treatments in people with eosinoph… Ended

2024-515162-13-00 Eosinophilic Asthma 5 2025-04-29
An open-label study to assess reduction of daily asthma medication with tezepelumab in patients 12 to 80 years of age with severe asthma Ended

2024-512113-41-00 Severe Asthma 5 2024-11-20
A Randomized, Double Blind, Active-Controlled Study on Efficacy and Safety of TEV-56248 in Patients with Asthma Ended

2023-505435-12-00 Asthma 5 2024-06-04
Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dos… Ended

2023-506000-50-00 Adult Patients with Moderate-to-Severe Asthma Uncontrol 4 2024-09-26
A Proof-of-Concept study to assess the efficacy, safety and tolerability of itepekimab (anti-IL-33 mAb) in participants with non-cystic fibr… Ended

2023-508663-70-00 Bronchiectasis 4 2024-06-18
A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) Ended

2023-503693-20-01 Severe eosinophilic asthma 5 2024-04-10
Efficacy and safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund maintenance therapy Ended

2022-502208-64-00 Asthma 4 2023-11-25
The efficacy and safety of two doses of CHF6001 DPI as add-on to maintenance COPD triple therapy Ended

2023-510174-13-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2021-06-17
The efficacy and the safety of two doses of CHF6001 for the treatment of Chronic Obstructive Pulmonary Disease (COPD) Ended

2023-510175-60-00 Chronic obstructive pulmonary disease (COPD) and Chron 5 2021-06-16